Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sanofi (SNYNF)

Sanofi (SNYNF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Sanofi (SNYNF) Gets a Buy from J.P. Morgan

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Sanofi, with a price target of €105.00. The company’s shares closed yesterday at $95.03.Elevate Your Investing...

SNYNF : 92.1980 (-1.16%)
SNY : 46.68 (-1.66%)
Sanofi’s Promising COPD Study: Lunsekimig’s Potential Impact

Sanofi ((SNYNF)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and...

SNYNF : 92.1980 (-1.16%)
Sanofi’s New COPD Treatment Study: A Potential Game-Changer?

Sanofi ((SNYNF)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and...

SNYNF : 92.1980 (-1.16%)
Sanofi’s New Study on SAR446597: A Potential Game-Changer for Age-related Macular Degeneration

Sanofi ((SNYNF)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and...

SNYNF : 92.1980 (-1.16%)
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Exelixis (EXEL) and Sanofi (OtherSNYNF)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Merus (MRUS – Research Report), Exelixis (EXEL – Research Report) and Sanofi (SNYNF – Research Report).Elevate Your...

SNYNF : 92.1980 (-1.16%)
MRUS : 90.00 (-7.14%)
EXEL : 44.06 (-3.04%)
Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Sanofi (SNYNF)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cytokinetics (CYTK – Research Report) and Sanofi (SNYNF – Research Report) with bullish sentiments.Elevate...

SNYNF : 92.1980 (-1.16%)
CYTK : 63.31 (-0.20%)
UBS Reaffirms Their Buy Rating on Sanofi (SNYNF)

UBS analyst Matthew Weston maintained a Buy rating on Sanofi today and set a price target of €105.00. The company’s shares closed last Wednesday at $99.00.Elevate Your Investing Strategy: Take advantage...

SNYNF : 92.1980 (-1.16%)
SNY : 46.68 (-1.66%)
Sanofi’s Phase 3 Study on Duvakitug: A Potential Game-Changer for Crohn’s Disease Treatment

Sanofi ((SNYNF)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and...

SNYNF : 92.1980 (-1.16%)
Sanofi’s Promising Phase 3 Study on Duvakitug for Ulcerative Colitis

Sanofi ((SNYNF)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and...

SNYNF : 92.1980 (-1.16%)
Sanofi’s Phase 3 Study on Duvakitug: A Potential Game-Changer for Ulcerative Colitis

Sanofi ((SNYNF)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and...

SNYNF : 92.1980 (-1.16%)

Barchart Exclusives

This Under-the-Radar Pet Stock Could Be the Biggest Meme Buy in January 2026
This pet stock is down more than 93% in five years, but recent takeover rumors have BARK spiking again. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar